M&A

argenx bets up to $1.15B to buy peptide specialist Unnatural Products

What's the deal? argenx has agreed to acquire Unnatural Products (UNP) for total potential consideration of up to $1.15 billion, buying a macrocyclic peptide discovery engine to broaden its immunology pipeline. The deal pairs $550 million in cash upfront with up to $595 million tied to development and regulatory milestones.

Who's involved? argenx is an Amsterdam-based immunology company behind VYVGART. Santa Cruz-based UNP, founded in 2016, develops orally delivered macrocyclic peptides aimed at targets that conventional drugs struggle to reach, and employs more than 50 people.

Why now? The deal builds on a research collaboration begun more than two years ago, under which argenx already held a minority stake in UNP. Buying the company converts that access into control of the platform and its team.

What's the endgame? argenx wants to combine UNP's peptides with its own antibody engineering to develop oral and long-acting medicines. UNP will continue operating from Santa Cruz as argenx's dedicated peptide discovery hub.

"UNP adds macrocyclic peptide capabilities that are highly complementary to our antibody engineering and creates new possibilities for oral and long-acting medicines," said Karen Massey, chief executive officer of argenx.

What could go wrong? The strategic promise remains early-stage. The acquired programs still need to demonstrate clinical results, and the bulk of the price is contingent on hitting milestones.

The signal: argenx is spending while its core franchise surges—it reported $2.8 billion in first-half 2026 product sales, up $1.1 billion year over year—signalling a bet that oral peptides can extend its reach beyond antibodies. The acquisition is expected to close by year-end, subject to customary conditions.

Read more: morningstar.com

Image credit: Unnatural Products

More top stories